Faith Davies, MD, FRCPath, is a professor of medicine amd the director of the Phase I Clinical Trials Program for both the Myeloma Institute and the Winthrop P. Rockefeller Cancer Institute at UAMS. She earned her medical degree from the University of Wales College of Medicine and completed her general medical training in Cardiff and Birmingham. She completed her Haematology Specialist training in Leeds and London. During this time, she also undertook research at the University of Leeds and the Dana-Farber Cancer Institute in Boston into the biology and treatment of multiple myeloma, concentrating on a number of potential new drugs and genetic technologies and their applications to myeloma.
Dr. Davies is recognized internationally for her focus on innovative targeted molecular therapies and her expertise in the treatment of relapsed refractory disease. Dr. Davies’ focus has been on combining laboratory-based research on targeted approaches to myeloma therapy with clinical work involving the introduction of new drugs in the clinical setting, with an emphasis has been on Phase I, II and II clinical trials. She is a member of the scientific advisory boards of both Myeloma UK and the International Myeloma Foundation.
Dr. Davies has received funding for her research from the Cancer Research UK, Kay Kendall Leukaemia Fund, Department of Health, Laeukemia Research Fund and British Society of Haematology. She has published over 100 papers in peer-reviewed journals, and has contributed to a number of book chapters and reviews on myeloma biology and treatment. She is also a reviewer for a number of international journals and grants.